Non-Viral Drug Delivery Systems Market

Non-Viral / Intracellular Drug Delivery Systems Market by Type of Molecule, Type of Biologics delivered, Type of Vehicle Used, Type of Therapeutic Area, Type of Payments and Key Geographical Regions: Industry Trends and Global Forecasts (2nd Edition), 2023-2035

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    252

  • Pages
    235

  • View Count
    19780

Non-Viral Drug Delivery Systems Market Overview

The non-viral drug delivery systems market size is estimated to be worth $7.1 billion in 2023 and is expected to grow at CAGR of 13.8% during the forecast period. In recent years, efficient methods for facilitation of intracellular drug delivery have become a prominent need within the modern pharmaceutical drug delivery market. Targeting intracellular protein and enzymes requires specialized approaches, such as cell penetrating peptides (CPP) and exosome-based drug delivery systems. These systems enable DNA delivery and gene delivery, offering targeted drug delivery possibilities. In fact, recent advancements in cell biology and drug delivery systems have identified potential therapeutic targets that were previously considered incurable due to their localization within the cell membrane. Intracellular therapies, including gene delivery and mRNA delivery, have emerged as promising alternatives to conventional treatments. Targeted drug delivery of a pharmacological substance to its intended physiological site of action ensures that adequate concentration of the therapeutics is made available, in order to elicit the desired clinical benefits and limit off-target / systemic toxicity. In fact, a study suggests that over 20% of the proteome, including oncogenic proteins, cell metabolism regulators, components of different signal transduction pathways and enzymes, is localized within the cell membrane. Further, considering the fact that only 10% of the human genome can selectively bind to small molecule pharmaceuticals, industry experts believe that intra-cellular therapies, particularly gene delivery and DNA delivery, present a promising alternative to conventional therapies. Furthermore, recent advancements in cell biology and intracellular drug delivery systems have led to the identification of several potential therapeutic targets for a variety of clinical disorders. As such, the market for non-viral drug delivery systems is anticipated to grow at a healthy CAGR over the forecast period.

List of Non Viral Drug Delivery Systems Providers from the research report of Roots Analysis Current market landscape of Intracellular Drug Delivery Systems Technologies domain, researched by Roots Analysis Competitive analysis of Non Viral Drug Delivery Systems, analyzed by Roots Analysis

Key Market Insights

The Non-Viral Drug Delivery Systems Market (2nd Edition), 2023-2035: Distribution by Type of Molecule Delivered (Small Molecules and Biologics), Type of Biologic Delivered (RNAi / mRNA, DNA Oligonucleotides, Antibodies, Proteins / Peptides), Type of Vehicle Used (Cell Penetrating Peptides, Extracellular Vesicles, Oligonucleotides, Nanoparticles and Polymers), Target Therapeutic Area (Infectious Diseases, Oncological Disorders, Genetic Disorders, Neurological Disorders, Hepatic Disorders, Cardiovascular Disorders and Other Disorders), Type of Payment (Upfront Payments and Milestone Payments) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts report features an extensive study of the current landscape, market size and the likely future opportunities of companies engaged in offering intracellular drug delivery technologies in the healthcare industry, over the forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the non-viral drug delivery systems market are briefly discussed below.

The Need for Non-Viral Drug Delivery Systems

Gene delivery systems are usually based on viral and non-viral vectors and known to enable the entry of pharmacologically active compounds into the matrix of the cytoplasm. Specifically, viral drug delivery systems utilize the ability of viruses to permit DNA delivery inside host cells. However, such drug delivery systems are often fraught with several challenges, such as immunogenicity, toxicity and reverse mutation. In order to overcome the aforementioned challenges and enable the delivery of intracellular therapies, including gene delivery and DNA delivery researchers have developed various non-viral drug delivery systems, including exosome-based drug delivery techniques, cell penetrating peptides (CPP) and nanoparticle-based processes. 

Non-Viral Drug Delivery Systems Market Analysis

Recently, Novartis received the US FDA approval for Leqvio (inclisiran), a first-in-class siRNA therapy for lower LDL cholesterol, which is delivered using an intracellular drug delivery technology. Other examples of recently approved gene therapies that involves intracellular gene delivery include (alphabetical order) ABECMA (idecabtagene vicleucel; manufactured by Celgene), BREYANZI (lisocabtagene maraleucel; manufactured by Juno Therapeutics) and KYMRIAH (tisagenlecleucel; manufactured by Novartis). Further, Feldan Therapeutics is at the forefront of developing innovative intra-cellular therapies.

Non-Viral Drug Delivery Systems Market Trends: Patents, Publications, Partnerships and More

Numerous technology developers have signed several strategic agreements with therapy developers in order to facilitate the development of drug formulations that can be delivered to the intracellular matrix. These drug developers are on the look-out for drug delivery systems for intracellular delivery. Additionally, close to 1,300 patents related to such technologies have been filed / granted in the past few years, demonstrating the continued innovation being carried out in the global market. Our market research suggests that at present, more than 20,000 oligonucleotide-based therapeutics focused studies, such as nucleic acid, are being conducted across the globe, including North America. These advancements in the pharmaceutical drug delivery market have the potential to provide targeted drug delivery systems and address a range of clinical disorders, including cancer and solid tumors. Driven by a growing demand for systems that can efficiently deliver therapeutic interventions in intracellular spaces, the non-viral drug delivery market size is likely to witness significant CAGR during the forecast period. 

Key Companies in Non-Viral Drug Delivery Systems Market

Examples of key companies engaged in the non-viral drug delivery systems industry (which have also been captured in this market report, arranged in alphabetical order) include Arcturus Therapeutics, Bio-Path, CureVac, Entos Pharmaceuticals, eTheRNA Immunotherapies, Matinas BioPharma, MDimune and PCI Biotech. This market report includes an easily searchable excel database of all the companies developing non-viral drug delivery systems, worldwide.

This image highlights the partnership activity undertaken by players engaged in Intracellular Drug Delivery Market This image provides information on patents that have been filed / granted related to Intracellular Drug Delivery Technologies This image describes Ansoff Matrix and Kalbach Innovation Model for Intracellular Drug Delivery Systems

Recent Developments in Non-Viral Drug Delivery Systems Market

Several recent developments have taken place in the non-viral drug delivery systems market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In June 2023, The Centre for Process Innovation (CPI) established a new UK Intracellular Drug Delivery Centre in order to develop new lipid nanoparticle (LNP) formulations for RNA medicine delivery to advance next-generation nano delivery systems. 
  • In May 2023, Innovation organization CPI entered into a partnership with Medicines Discovery Catapult, the University of Strathclyde, the University of Liverpool and Imperial College London to develop novel drug delivery technologies to strengthen RNA vaccines and therapeutics.
  • In April 2023, Vitarka Therapeutics raised USD 1.58 million in equity from venture capital firm SOSV to develop combination medicines using RNAi therapies and a non-viral drug delivery platform.

Scope of the Report

The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments, as defined in the below table:

Report Attribute Details

Forecast Period

2023-2035

Type of Molecule Delivered Small Molecule (s), Biologic (s)
Type of Biologic Delivered Antibodies, DNA, Protein / Peptide, RNA
Target Therapeutic Area

Infectious diseases, Oncological disorders, Genetic disorders, Neurological disorders, Hepatic disorders, Cardiovascular disorders and Other disorders 

Type of Vehicle Used  Cell Penetrating Peptides, Extracellular Vesicles, Oligonucleotides, Nanoparticles and Polymers 
Type of Payment Model Upfront Payments and Milestone Payments 
Key Geographical Regions

North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World

Key Companies Profiled  Arcturus Therapeutics, Bio-Path Holdings, CureVac, Entos Pharmaceuticals, eTheRNA, Matinas BioPharma, MDimune and PCI Biotech
Customization Scope 15% Free Customization Option (equivalent to 5 analyst working days)
PowerPoint Presentation (Complimentary) Available
Excel Data Packs (Complimentary) Market Landscape Analysis, Company Competitiveness Analysis, Partnership and Collaboration Analysis, Patent Analysis, Market Forecast and Opportunity Analysis

The market research report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market report includes:

  • An executive summary of the key insights captured during our research, offering a high-level view on the current state of the non-viral drug delivery systems market and its likely evolution in the short to mid and long term.
  • A brief introduction to important concepts related to non-viral intracellular drug delivery, featuring information on various types of non-viral drug delivery systems and its primary applications in the healthcare market, along with details related to the recent advancements that have been reported in this market space.
  • A detailed review of the overall market landscape of non-viral drug delivery systems, featuring an in-depth analysis based on several relevant parameters, such as therapeutic portfolio, type of molecule delivered (small molecules and biologics), type of biologic delivered (antibodies, DNA, RNA and proteins / peptides), type of interaction (co-administration, conjugation, encapsulation and others) and type of vehicle used (cell penetrating peptides, extracellular vesicles, oligonucleotides, nanoparticles, polymers). In addition, it features a list of technology developers and a detailed analysis based on year of establishment, company size, type of company and geographical location.
  • An in-depth analysis, highlighting the contemporary non-viral drug delivery market trends, using four schematic representations, including a waffle chart representation, (highlighting the distribution of various types of vehicles used for delivering payloads), a heat map representation (based on company size and type of molecule delivered), a vertical stacked column bar chart representation (location of headquarters and type of service provider), a vertical column clustered chart representation (based on company size and location of headquarters).
  • An insightful company competitiveness analysis of non-viral drug delivery systems providers, taking into consideration various relevant parameters, such as years of experience and portfolio strength (in terms of number of technologies offered, type of biologics delivered and type of linkage) and partnership strength (in terms of number of partnerships, partnership year, partnerships based on geographies, type of partnerships, therapeutic area, payment portfolio and type of biologics delivered).
  • Elaborate profiles of prominent players engaged in offering non-viral drug delivery technologies, across North America, Europe and Asia. Each company profile features a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters and key members of the executive team), details related to its recent developments and an informed future outlook. 
  • An in-depth analysis of the various patents that have been filed / granted patent related to intracellular drug delivery technologies, based on various parameters, such as type of patent, publication year, granted patents, filed patents, patent publication year and type of players, issuing authority, patent focus, patent age and CPC symbols (in terms of the size of intellectual property portfolio). Further, it features a three-dimensional bubble analysis (based on patent citation count, publication year and extended geographical reach), patent benchmarking analysis and a detailed patent valuation analysis
  • An insightful analysis of various partnerships inked between stakeholders engaged within the non-viral drug delivery systems market, based on several relevant parameters, such as year of partnership, type of partner (industry and non-industry), type of partnership (Research and Development, Research, development and commercialization, product development, product development and commercialization, product development and manufacturing, product development and manufacturing, commercialization, manufacturing, acquisition / merger and others), purpose of partnership (technology licensing agreements, technology evaluation agreements, technology integration agreements, technology utilization agreements, acquisitions / mergers and others), therapeutic area (oncological disorders, infectious diseases, genetic disorders, hepatic disorders, neurological disorders, cardiovascular disorders, ophthalmic diseases, pulmonary diseases, metabolic disorders, immunological disorders and others), type of payment model (upfront payments, milestone payments, royalties and others), type of molecule delivered (small molecules, biologics and both), type of biologic delivered (antibodies, RNA, DNA and proteins / peptides), most active players (in terms of number of deals inked), most popular technologies (in terms of number of deals inked for technologies) and regional distribution of partnership activity that have been undertaken in this industry, during the forecast period 2015-2022.
  • An insightful framework which provides four zones of evaluation and product portfolio matrix based on various parameters, such as number of drugs in the pipeline, number of companies, deal amount, partnership activity, trends highlighted in number of grants, number of publications, google hits and qualitative scoring. It also provides a Kalbach, Ansoff and BCG matrix for respective non-viral drug delivery technologies currently employed by stakeholders.
This image highlights the examples of deal financings of Intracellular Drug Delivery Technologies The current and future market trends of Intracellular Drug Delivery Technologies according to Roots Analysis The market segments of Intracellular Drug Delivery Technologies domain based on the research report of Roots Analysis

One of the key objectives of this market report was to estimate the existing market opportunity and the future growth potential of the non-viral drug delivery systems market over the coming years. We have provided an informed estimate on the likely financial evolution of the market in the short to mid-term and long term, for the forecast period 2022-2035. Additionally, the market report features the likely distribution of the current and upcoming opportunity segmented across important parameters, such as type of molecule delivered (small molecules and biologics), type of biologic delivered (antibodies, RNA, DNA and proteins / peptides), type of vehicle used (Cell Penetrating Peptides, Extracellular Vesicles, Oligonucleotides, Nanoparticles and Polymers), target therapeutic area (infectious diseases, oncological disorders, genetic disorders, neurological disorders, hepatic disorders, cardiovascular disorders and other disorders), type of payment model (upfront payments and milestone payments) and key geographical regions (North America, Europe, Asia, Latin America, Middle East and North Africa and rest of the world).

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What are non-viral drug delivery systems?

Answer: Non-viral drug delivery systems, including exosome-based drug delivery techniques, cell penetrating peptides (CPP) and nanoparticle-based processes.

Question 2: How big is the non-viral drug delivery systems market?

Answer: The non-viral drug delivery systems market size is estimated to be worth $7.1 billion in 2023.

Question 3: What is the anticipated growth rate of non-viral drug delivery systems market?

Answer: The non-viral drug delivery systems market is expected to grow at CAGR of 13.8% during the forecast period.

Question 4: Who are the leading companies in the non-viral drug delivery systems industry?

Answer: Arcturus Therapeutics, Bio-Path, CureVac, Entos Pharmaceuticals, eTheRNA Immunotherapies, Matinas BioPharma, MDimune and PCI Biotech.

Question 5: How many patents have been filed for non-viral drug delivery systems?

Answer: Close to 1,300 patents related to such technologies have been filed / granted in the past few years.

PRICING DETAILS

USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com